Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: A re-examination of the situation

Minerva Gastroenterologica e Dietologica

Volumn 63, Issue 1, 2017, Pages 55-61

  Willuweit, Katharina ^a   Canbay, Ali ^a   Gerken, Guido ^a   Timm, Jörg ^b   Paul, Andreas ^a   Treckmann, Jürgen ^a   Herzer, Kerstin ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Hepacivirus; Liver transplantation; Sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BOCEPREVIR; CREATININE; DACLATASVIR; DASABUVIR; INTERFERON; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PREDNISONE; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TACROLIMUS; TELAPREVIR; ANTIVIRUS AGENT; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; FIBROSIS; GENOTYPE; GLOMERULUS FILTRATION RATE; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY RATE; PHYLOGENY; POLYMERASE CHAIN REACTION; QUALITY OF LIFE; REINFECTION; RETROSPECTIVE STUDY; REVIEW; SUSTAINED VIROLOGIC RESPONSE; VIRUS LOAD; BLOOD; CARCINOMA, HEPATOCELLULAR; DONOR; GENETICS; HEPACIVIRUS; HEPATITIS C; LIVER NEOPLASMS; RECURRENT DISEASE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; RECURRENCE; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; TISSUE DONORS; VIRAL LOAD;

EID: 85012930625     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: 10.23736/S1121-421X.16.02347-3     Document Type: Review

References (38)

1. Berenguer M. Viral hepatitis after liver transplantation. Hepatol Res 2007;37 Suppl 2:S279-86.
2. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 2011;54:3-5.
3. Forns X, Berenguer M, Herzer K, Sterneck M, Donato MF, Andreone P, et al. On-Treatment Virologic Response and Tolerability of Simeprevir, Daclatasvir and Ribavirin in Patients with Recurrent Hepatitis C Virus Genotype 1b Infection after Orthotopic Liver Transplantation (Olt): Interim Data from the Phase Ii Saturn Study. Journal of Hepatology 2015;62:S191-S2.
4. Herzer K, Papadopoulos-Kohn A, Walker A, Achterfeld A, Paul A, Canbay A, et al. Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. Digestion 2015;91:326-33.
5. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, et al. An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. New England Journal of Medicine 2014;371:2375-82.
6. Poordad F, Schiff E, Vierling J, Landis C, Fontana R, Yang R, et al. A Phase 3 Study (Ally-1) of Daclatasvir, Sofosbuvir, and Ribavirin for Treatment of Hcv in Advanced Cirrhosis or Posttransplant Hcv Recurrence. Transplant International 2015;28:21-2.
7. Herzer K, Welzel T, Spengler U, Hinrichsen H, Umgelter A, Gruner N, et al. Safety and Efficacy of Daclatasvir Plus Sofosbuvir with or without Ribavirin for Hepatitis C Post-Transplant: Interim Results from the Compassionate Use Program. Transplant International 2015;28:35.
8. Mandal AK, Kraus ES, Samaniego M, Rai R, Humphreys SL, Ratner LE, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000;14:391-6.
9. Feray C, Shouval D, Samuel D. Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? Gastroenterology 1999;117:263-5.
10. Pereira BJ, Levey AS. Hepatitis C infection in cadaver organ donors: strategies to reduce transmission of infection and prevent organ waste. Pediatr Nephrol 1995;9 Suppl:S23-8.
11. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78.
12. Butt AA, Yan P, Shaikh OS, Freiberg MS, Lo Re V, 3rd, Justice AC, et al. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 2015;22:691-700.
13. Sarrazin C, Berg T, Buggisch P, Dollinger MM, Hinrichsen H, Hofer H, et al. [S3 guideline hepatitis C addendum]. Z Gastroenterol 2015;53:320-34.
14. Chahine EB, Sucher AJ, Hemstreet BA. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. Ann Pharmacother 2016.
15. Papudesu C, Kottilil S, Bagchi S. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatol Int 2016.
16. Fontana RJ, Brown R, Herzer J, Stauber K, Moreno- Zamora RE, Londono A, et al. Daclatasvir (Dcv) Combined with Sofosbuvir (Sof) or Simeprevir (Smv) in Liver Transplant (Lt) Recipients with Severe Recurrent Hcv Genotype 1 Infection. Journal of Hepatology 2015;62:S629-S.
17. Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS 2015;29:53-8.
18. Poordad F, Schiff E, Vierling J, Landis C, Fontana R, Yang R, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: phase 3 ALLY-1 study. Journal of Viral Hepatitis 2015;22:30-1.
19. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016.
20. Buti M, Llaneras J, Riveiro-Barciela M, Esteban R. Therapy for hepatitis C genotype 3: moving forward. J Viral Hepat 2015;22:683-90.
21. Feld JJ, Foster GR. Second generation direct-acting antivirals - Do we expect major improvements? J Hepatol 2016;65:S130-42.
22. Moradpour D, Grakoui A, Manns MP. Future landscape of hepatitis C research - Basic, translational and clinical perspectives. J Hepatol 2016;65:S143-55.
23. Herzer K, Gerken G. When and How to Treat HCV Infection with the New Antivirals before or after Liver Transplantation. Visc Med 2016;32:258-62.
24. Walker A SH, Groten S, Ross Rs, Scherbaum N, Timm J Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany. Journal of clinical virology 2015;70:43-5.
25. Charlton M, Gane E, Manns MP, Brown RS, Jr., Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148:108-17.
26. Lai JC, O'leary JG, Trotter JF, Verna EC, Brown RS, Jr., Stravitz RT, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012;18:532-8.
27. Burr AT, Li Y, Tseng JF, Saidi RF, Bozorgzadeh A, Shah SA. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg 2011;35:1590-5.
28. Northup PG, Argo CK, Nguyen DT, Mcbride MA, Kumer SC, Schmitt TM, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int 2010;23:1038-44.
29. Velidedeoglu E, Desai NM, Campos L, Olthoff KM, Shaked A, Nunes F, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002;73:582-7.
30. Alvaro E, Abradelo M, Fuertes A, Manrique A, Colina F, Alegre C, et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplant Proc 2012;44:1475-8.
31. Ballarin R, Cucchetti A, Spaggiari M, Montalti R, Di Benedetto F, Nadalin S, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus- positive donors: a European multicentric case-control study. Transplantation 2011;91:1265-72.
32. O'leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int 2012;25:825-9.
33. Mccaughan GW. Immunosuppression for HCV following liver transplantation: enough is just enough. Transplantation 2004;78:1413-4.
34. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-84.
35. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459-65.
36. Ciria R, Pleguezuelo M, Khorsandi SE, Davila D, Suddle A, Vilca-Melendez H, et al. Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol 2013;5:237-50.
37. Zimmermann T, Beckebaum S, Berg C, Berg T, Braun F, Eurich D, et al. [Expert recommendations: Hepatitis C and transplantation]. Z Gastroenterol 2016;54:665-84.
38. European Association for the Study of the Liver. Electronic Address EEE. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2016.